Tilray Brands (NASDAQ:TLRY) Stock Price Down 2.7% – Should You Sell?

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price fell 2.7% on Tuesday. The company traded as low as $3.25 and last traded at $3.27. Approximately 4,052,940 shares changed hands during mid-day trading, a decline of 4% from the average session volume of 4,238,469 shares. The stock had previously closed at $3.36.

Key Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Portugal facility receives testing approval: Tilray Medical said Portugal’s INFARMED regulator authorized its Cantanhede facility to conduct microbiological and chemical/physical quality testing in-house under EU-GMP standards. The approval could reduce reliance on outside laboratories, shorten product-release timelines and support distribution into regulated international medical-cannabis markets. Tilray Medical Strengthens Global Medical Cannabis Supply Chain
• Neutral Sentiment: BrewDog is lifting reported revenue: Coverage of Tilray’s fiscal Q1 results noted that the acquired BrewDog beer operations contributed to revenue growth, while management expects the beer assets and international cannabis business to support future expansion. However, the acquisition’s contribution does not yet resolve broader profitability concerns. BrewDog Acquisition Boosts Tilray’s Stock Q1 Performance
• Negative Sentiment: Core cannabis performance weakened: Analysts highlighted that Q1 revenue growth was driven primarily by BrewDog, while cannabis revenue declined approximately 13%. Reports also described a disappointing revenue performance relative to expectations and a swing to an adjusted loss. Tilray Q1 Not Looking Good
• Negative Sentiment: Cash burn and dilution remain concerns: Tilray reportedly used $23.4 million in cash during the quarter, remained unprofitable and generated negative free cash flow. Shares outstanding increased more than 31% year over year, raising concern about shareholder dilution and the company’s path to sustainable earnings. Three Huge Red Flags From Tilray’s Q1 Earnings Report
• Negative Sentiment: Analyst caution adds pressure: At least one analyst reduced a price target, reinforcing investor concerns about declining cannabis sales, losses, cash usage and execution risks despite the company’s expansion initiatives. Tilray Analyst Price Target Cut

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. ATB Cormark Capital Markets reduced their price target on shares of Tilray Brands from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Monday, September 21st. TD Securities upgraded shares of Tilray Brands to a “strong-buy” rating in a research report on Friday, July 31st. Zacks Research downgraded shares of Tilray Brands from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 29th. Canaccord Genuity Group dropped their target price on shares of Tilray Brands from $4.50 to $4.00 and set a “hold” rating for the company in a research note on Friday. Finally, TD Cowen reduced their target price on shares of Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $5.90.

Tilray Brands Stock Down 2.7%

The business’s 50-day moving average is $4.26 and its two-hundred day moving average is $4.99. The firm has a market capitalization of $445.37 million, a price-to-earnings ratio of -2.34 and a beta of 1.91. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.11 and a current ratio of 1.88.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings data on Tuesday, July 28th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.42). Tilray Brands had a negative net margin of 16.91% and a negative return on equity of 10.39%. The business had revenue of $281.71 million during the quarter, compared to analyst estimates of $246.30 million. On average, equities analysts anticipate that Tilray Brands, Inc. will post -0.48 earnings per share for the current year.

Insider Activity

In related news, CFO Carl Merton acquired 10,000 shares of the stock in a transaction dated Tuesday, August 4th. The stock was bought at an average price of $4.62 per share, with a total value of $46,200.00. Following the completion of the transaction, the chief financial officer directly owned 139,753 shares of the company’s stock, valued at approximately $645,658.86. The trade was a 7.71% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have acquired a total of 15,000 shares of company stock worth $69,225 over the last ninety days. 1.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Tilray Brands

A number of large investors have recently added to or reduced their stakes in TLRY. BlackRock Inc. acquired a new stake in shares of Tilray Brands in the 2nd quarter valued at about $2,073,000. Legal & General Group Plc bought a new stake in shares of Tilray Brands in the second quarter valued at about $381,000. Squarepoint Ops LLC acquired a new position in shares of Tilray Brands during the second quarter worth about $192,000. Jupiter Topco LLC acquired a new position in shares of Tilray Brands during the second quarter worth about $188,000. Finally, Hsbc Holdings PLC acquired a new position in shares of Tilray Brands during the second quarter worth about $182,000. Institutional investors own 9.35% of the company’s stock.

About Tilray Brands

Tilray Brands, Inc is a global consumer packaged goods company focused on cannabis, beverage alcohol, wellness and consumer products. The company develops, produces, distributes and markets a range of cannabis products, including dried flower, pre-rolls, vapes, edibles and medical cannabis products, subject to applicable regulations in the markets it serves.

Tilray also operates beverage alcohol businesses, including craft beer, spirits and other alcoholic beverages. Its portfolio has included brands such as SweetWater Brewing Company, Montauk Brewing Company and Breckenridge Distillery.